Cyclodextrin-siRNA conjugates as versatile gene silencing agents.

Cyclodextrin-siRNA conjugates as versatile gene silencing agents. Eur J Pharm Sci. 2017 Nov 27;: Authors: Malhotra M, Gooding M, Evans JC, O'Driscoll D, Darcy R, O'Driscoll C Abstract Functional siRNAs (luciferase and PLK1) have been conjugated to β-cyclodextrin and the ability of the conjugates to retain gene knockdown activity has been assessed by delivery to cancer cell lines using various formulations. Initially two formulations used complexation with polycations, namely Lipofectamine 2000 and an amphiphilic polycationic cyclodextrin. Gene knockdown results for human glioblastoma cells (U87) and prostate cancer cells (PC3, DU145) showed that conjugation to the cyclodextrin did not reduce gene silencing by the RNA. A third mode of delivery involved formation of targeted nanoparticles in which the conjugate was first complexed with adamantyl-PEG-ligands (targeting ligand RVG peptide or dianisamide) by adamantyl inclusion in the cyclodextrin cavities of the conjugates, followed by charge neutralisation with the cationic polymer chitosan. Enhanced knockdown was achieved by these ligand-targeted formulations. In summary, while this study illustrated the gene silencing efficacy of a simple cyclodextrin-siRNA conjugate it is envisaged that future studies will explore the use of conjugates with a modified cyclodextrin which would be self-delivering. Detailed data such as stability, lysosomal escape etc. will then be reported for each conjugate, since th...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research

Related Links:

ANAHEIM, CA - Adding an interim prostate-specific membrane antigen (PSMA)-PET...Read more on AuntMinnie.comRelated Reading: Could Ga-68 PSMA PET become essential for prostate cancer? Ga-68 PSMA PET/CT for prostate wins Australian favor Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Novel nanoSPECT/CT radionuclide could aid cancer therapy SNMMI: Early prostate cancer therapy extends lives
Source: Headlines - Category: Radiology Source Type: news
Abstract PROBLEM IDENTIFICATION: To determine best practices for managing hot flashes associated with androgen deprivation therapy (ADT) in men with prostate cancer. LITERATURE SEARCH: The CINAHL®, Embase®, PsycINFO®, PubMed®, and Scopus® databases were used to identify randomized controlled trials (RCTs) and quasiexperimental studies published between January 1994 and June 2018. DATA EVALUATION: Using the Cochrane Handbook for Systematic Reviews of Interventions, the authors reviewed 15 studies examining the effects of pharmacologic or complementary and alternative medicine intervent...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Authors: Miranda J, Viñal D, Pinto Á Abstract The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the recent years with the approval of several new drugs. Together with other treatment modalities including chemotherapy, hormonal therapy and immunotherapy, radiopharmaceuticals have recently been incorporated to the therapeutic scenario of prostate cancer with the approval of Radium 223 dichloride (Ra-223) for the treatment of mCRPC patients with symptomatic bone metastasis and no visceral metastases. Radiopharmaceuticals have long been used...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Authors: Murray NP, Aedo S, Fuentealba C, Reyes E, Minzer S, Salazar A Abstract INTRODUCTION: Minimal residual disease (MRD) is that which remains after curative therapy for prostate cancer. It has the potential for growth and later cause metastasis. After radical prostatectomy, the detection of circulating prostate cells (CPCs) and bone marrow micro-metastasis could represent different types of MRD. We proposed to determine the biochemical failure free survival rates, the time to biochemical failure after 10 years of follow-up and the presence of CPCs and micro-metastasis in patients treated with RP for pathologic...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
CONCLUSIONS: Differed strategies still accounted for a small percentage of treatments. PR and RT/BT were of choice in patients with localized stages of the disease and younger than 70 years. More advanced stages and older patients were treated with HT mainly. Age is postulated as the main factor involved in therapeutic decision making. PMID: 31223124 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
In the treatment paradigm for prostate cancer, the pendulum has swung towards increasing use of active surveillance (AS) for lower risk disease, reflected by the most recent guidelines from the American Urological Association.1 These recommendations are supported largely by level-1 evidence from the PIVOT and ProtecT trials, which revealed similar mortality outcomes between observation and primary treatment for patients with clinically localized disease.2,3 In the present study, the authors characterize the management patterns of a unique, sizable cohort of patients with very low, low, or intermediate risk prostate cancer ...
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Publication date: Available online 22 June 2019Source: European UrologyAuthor(s): Zsofia Kote-Jarai, Daniel A. Leongamornlert, Edward J. Saunders, David V. Conti, Rosalind A. Eeles
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Guan Y, Guan X, An H, Baihetiya A, Wang W, Shao W, Yang H, Wang Y Abstract Prostate cancer is an important hormone-dependent cancer affecting men. In the initial stages, prostate cancer is often treated using hormone therapy, including bicalutamide. Despite the initial effectiveness of this therapy, the tumor eventually acquires resistance, resulting in recurrence of castration-resistant prostate cancer (CRPC). Dysregulation of microRNA (miRNA) function is one of the putative underlying mechanisms of hormone therapy resistance. Reports have shown that miRNAs act as tumor suppressors in patients with prosta...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Using magnetic resonance imaging in tandem with the traditional ultrasound method can significantly improve prostate cancer detection, according to a  study recently published inJAMA Surgery.Prostate cancer has been traditionally diagnosed with only ultrasound. Physicians use the technique for tissue biopsy. However, this method alone can ’t detect certain tumors. Historically, MRI-based biopsy practices are practical because they can detect precise lesions on the prostate. Yet, not all tumors appear on MRI, making it difficult to identify all kinds of cancer. Researchers from the University of California Los An...
Source: radRounds - Category: Radiology Authors: Source Type: blogs
ConclusionsIn this phase 1/2 study, hypofractionated postoperative radiation therapy seems to have good clinical efficacy without significant late toxicity. Phase 3 studies are warranted.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Nanotechnology | Prostate Cancer | Study